|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu W, Wang Y, Jiang Y, Zhang W and Li Y:
Genetic analysis and clinicopathological features of ALK-rearranged
renal cell carcinoma in a large series of resected Chinese renal
cell carcinoma patients and literature review. Histopathology. Feb
15–2017.Epub ahead of print. View Article : Google Scholar
|
|
3
|
Golovastova MO, Korolev DO, Tsoy LV,
Varshavsky VA, Xu WH, Vinarov AZ, Zernii EY, Philippov PP and
Zamyatnin AA Jr: Biomarkers of renal tumors: The current state and
clinical perspectives. Curr Urol Rep. 18:32017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choueiri TK and Motzer RJ: Systemic
therapy for metastatic renal-cell carcinoma. N Engl J Med.
376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mirsaeidi M, Gidfar S, Vu A and
Schraufnagel D: Annexins family: Insights into their functions and
potential role in pathogenesis of sarcoidosis. J Transl Med.
14:892016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Laohavisit A and Davies JM: Annexins. New
Phytol. 189:40–53. 2011. View Article : Google Scholar
|
|
7
|
Bouter A, Carmeille R, Gounou C, Bouvet F,
Degrelle SA, Evain-Brion D and Brisson AR: Review: Annexin-A5 and
cell membrane repair. Placenta. 36(Suppl 1): S43–S49. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lauritzen SP, Boye TL and Nylandsted J:
Annexins are instrumental for efficient plasma membrane repair in
cancer cells. Semin Cell Dev Biol. 45:32–38. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fatimathas L and Moss SE: Annexins as
disease modifiers. Histol Histopathol. 25:527–532. 2010.PubMed/NCBI
|
|
10
|
Mussunoor S and Murray GI: The role of
annexins in tumour development and progression. J Pathol.
216:131–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gerke V, Creutz CE and Moss SE: Annexins:
Linking Ca2+ signalling to membrane dynamics. Nat Rev
Mol Cell Biol. 6:449–461. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rescher U and Gerke V: Annexins - unique
membrane binding proteins with diverse functions. J Cell Sci.
117:2631–2639. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hayes MJ and Moss SE: Annexins and
disease. Biochem Biophys Res Commun. 322:1166–1170. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Peng B, Guo C, Guan H, Liu S and Sun MZ:
Annexin A5 as a potential marker in tumors. Clin Chim Acta.
427:42–48. 2014. View Article : Google Scholar
|
|
15
|
Guo W, Xue J, Shi J, Li N, Shao Y, Yu X,
Shen F, Wu M, Liu S and Cheng S: Proteomics analysis of distinct
portal vein tumor thrombi in hepatocellular carcinoma patients. J
Proteome Res. 9:4170–4175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cojocaru E, Lozneanu L, Giuşcă SE, Căruntu
ID and Danciu M: Renal carcinogenesis - insights into signaling
pathways. Rom J Morphol Embryol. 56:15–19. 2015.
|
|
17
|
Hong M, Park N and Chun YJ: Role of
annexin a5 on mitochondria-dependent apoptosis induced by
tetramethoxystilbene in human breast cancer cells. Biomol Ther
(Seoul). 22:519–524. 2014. View Article : Google Scholar
|
|
18
|
Bae SM, Lee CH, Cho YL, Nam KH, Kim YW,
Kim CK, Han BD, Lee YJ, Chun HJ and Ahn WS: Two-dimensional gel
analysis of protein expression profile in squamous cervical cancer
patients. Gynecol Oncol. 99:26–35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xue G, Hao LQ, Ding FX, Mei Q, Huang JJ,
Fu CG, Yan HL and Sun SH: Expression of Annexin A5 is associated
with higher tumor stage and poor prognosis in colorectal
adenocarcinomas. J Clin Gastroenterol. 43:831–837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rajcevic U, Petersen K, Knol JC, Loos M,
Bougnaud S, Klychnikov O, Li KW, Pham TV, Wang J, Miletic H, et al:
iTRAQ-based proteomics profiling reveals increased metabolic
activity and cellular cross-talk in angiogenic compared with
invasive glioblastoma phenotype. Mol Cell Proteomics. 8:2595–2612.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sofiadis A, Becker S, Hellman U,
Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G,
Foukakis T, Hoog A, et al: Proteomic profiling of follicular and
papillary thyroid tumors. Eur J Endocrinol. 166:657–667. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Zhang Y, Liu X, Ma J, Liu P, Hu C
and Zhang G: Annexin A5 inhibits diffuse large B-cell lymphoma cell
invasion and chemoresistance through phosphatidylinositol 3-kinase
signaling. Oncol Rep. 32:2557–2563. 2014.PubMed/NCBI
|
|
23
|
Yu JS and Cui W: Proliferation, survival
and metabolism: The role of PI3K/AKT/mTOR signalling in
pluripotency and cell fate determination. Development.
143:3050–3060. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Wu C, Chen N, Gu H, Yen A, Cao L,
Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted
therapy for glioblastoma. Oncotarget. 7:33440–33450.
2016.PubMed/NCBI
|
|
25
|
Wu L, Yang L, Xiong Y, Guo H, Shen X,
Cheng Z, Zhang Y, Gao Z and Zhu X: Annexin A5 promotes invasion and
chemoresistance to temozolomide in glioblastoma multiforme cells.
Tumour Biol. 35:12327–12337. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jin K, Li T, van Dam H, Zhou F and Zhang
L: Molecular insights into tumour metastasis: Tracing the dominant
events. J Pathol. Dec 30;2016Epub ahead of print. View Article : Google Scholar
|
|
27
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Itoigawa Y, Harada N, Harada S, Katsura Y,
Makino F, Ito J, Nurwidya F, Kato M, Takahashi F, Atsuta R, et al:
TWEAK enhances TGF-β-induced epithelial-mesenchymal transition in
human bronchial epithelial cells. Respir Res. 16:482015. View Article : Google Scholar
|
|
29
|
Kapral M, Wawszczyk J, Jurzak M, Dymitruk
D and Weglarz L: Evaluation of the expression of metalloproteinases
2 and 9 and their tissue inhibitors in colon cancer cells treated
with phytic acid. Acta Pol Pharm. 67:625–629. 2010.
|
|
30
|
Wang Q, Yu W, Huang T, Zhu Y and Huang C:
RUNX2 promotes hepatocellular carcinoma cell migration and invasion
by upregulating MMP9 expression. Oncol Rep. 36:2777–2784.
2016.PubMed/NCBI
|
|
31
|
Wu X, Tang Y, Huang W and Wu Y:
Identification of proteins interacting with multidrug resistance
protein in gastric cancer. World J Gastroenterol. 19:3568–3673.
2011.
|
|
32
|
Deng S, Wang J, Hou L, Li J, Chen G, Jing
B, Zhang X and Yang Z: Annexin A1, A2, A4 and A5 play important
roles in breast cancer, pancreatic cancer and laryngeal carcinoma,
alone and/or synergistically. Oncol Lett. 5:107–112. 2013.
|
